Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases

Kiyong Na, Hyun Soo Kim, Hyo Sup Shim, Jong Hee Chang, Seok Gu Kang, Se Hoon Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The TruSight Tumor 170 (TST-170) panel consists of a DNA workflow for the identification of single-nucleotide variants, small insertions and deletions, and copy number variation, as well as a panel of 55 genes for a RNA workflow for the identification of splice variants and gene fusions. To date, the application of TST-170 in diffuse gliomas (DGs) has not been described. Methods: We analyzed 135 samples of DG, which were diagnosed by WHO criteria based on histological features and conventional molecular tests including immunostaining, 1p/19q FISH, and analysis of MGMT methylation and TERT promoter mutation. Results: A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant. DNA analysis enabled the detection of all mutations identified in these samples by conventional techniques, and the results were highly comparable to the known mutations in each subtype. RNA analysis detected four fusion genes including PTPRZ1–MET, FGFR3–TACC3, FAM131B–BRAF, and RET–CCDC6 and one splicing variant (EGFR vIII mutant). Clustered copy number loss in 1p and 19q loci genes were detected in 1p/19q-codeleted OD. Conclusions: The application of TST-170 panel based NGS in clinical and laboratory setting is expected to improve diagnostic accuracy and prognostication. Most benefits are expected in IDH-wildtype DG, a group of genetically heterogenous tumors harboring DNA sequence changes, copy number alterations, and fusions in a large number of oncogenes and tumor suppressor genes.

Original languageEnglish
Pages (from-to)445-454
Number of pages10
JournalJournal of Neuro-Oncology
Volume142
Issue number3
DOIs
Publication statusPublished - 2019 May 1

Fingerprint

Oligodendroglioma
Glioma
Workflow
Gene Fusion
Astrocytoma
Glioblastoma
Mutation
Neoplasms
RNA
DNA
Tumor Suppressor Genes
Oncogenes
Methylation
Genes
Nucleotides

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

@article{430556b1ae5c4913bbfaefb50ef10daa,
title = "Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases",
abstract = "Purpose: The TruSight Tumor 170 (TST-170) panel consists of a DNA workflow for the identification of single-nucleotide variants, small insertions and deletions, and copy number variation, as well as a panel of 55 genes for a RNA workflow for the identification of splice variants and gene fusions. To date, the application of TST-170 in diffuse gliomas (DGs) has not been described. Methods: We analyzed 135 samples of DG, which were diagnosed by WHO criteria based on histological features and conventional molecular tests including immunostaining, 1p/19q FISH, and analysis of MGMT methylation and TERT promoter mutation. Results: A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant. DNA analysis enabled the detection of all mutations identified in these samples by conventional techniques, and the results were highly comparable to the known mutations in each subtype. RNA analysis detected four fusion genes including PTPRZ1–MET, FGFR3–TACC3, FAM131B–BRAF, and RET–CCDC6 and one splicing variant (EGFR vIII mutant). Clustered copy number loss in 1p and 19q loci genes were detected in 1p/19q-codeleted OD. Conclusions: The application of TST-170 panel based NGS in clinical and laboratory setting is expected to improve diagnostic accuracy and prognostication. Most benefits are expected in IDH-wildtype DG, a group of genetically heterogenous tumors harboring DNA sequence changes, copy number alterations, and fusions in a large number of oncogenes and tumor suppressor genes.",
author = "Kiyong Na and Kim, {Hyun Soo} and Shim, {Hyo Sup} and Chang, {Jong Hee} and Kang, {Seok Gu} and Kim, {Se Hoon}",
year = "2019",
month = "5",
day = "1",
doi = "10.1007/s11060-019-03114-1",
language = "English",
volume = "142",
pages = "445--454",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma : a single institutional experience of 135 cases. / Na, Kiyong; Kim, Hyun Soo; Shim, Hyo Sup; Chang, Jong Hee; Kang, Seok Gu; Kim, Se Hoon.

In: Journal of Neuro-Oncology, Vol. 142, No. 3, 01.05.2019, p. 445-454.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma

T2 - a single institutional experience of 135 cases

AU - Na, Kiyong

AU - Kim, Hyun Soo

AU - Shim, Hyo Sup

AU - Chang, Jong Hee

AU - Kang, Seok Gu

AU - Kim, Se Hoon

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Purpose: The TruSight Tumor 170 (TST-170) panel consists of a DNA workflow for the identification of single-nucleotide variants, small insertions and deletions, and copy number variation, as well as a panel of 55 genes for a RNA workflow for the identification of splice variants and gene fusions. To date, the application of TST-170 in diffuse gliomas (DGs) has not been described. Methods: We analyzed 135 samples of DG, which were diagnosed by WHO criteria based on histological features and conventional molecular tests including immunostaining, 1p/19q FISH, and analysis of MGMT methylation and TERT promoter mutation. Results: A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant. DNA analysis enabled the detection of all mutations identified in these samples by conventional techniques, and the results were highly comparable to the known mutations in each subtype. RNA analysis detected four fusion genes including PTPRZ1–MET, FGFR3–TACC3, FAM131B–BRAF, and RET–CCDC6 and one splicing variant (EGFR vIII mutant). Clustered copy number loss in 1p and 19q loci genes were detected in 1p/19q-codeleted OD. Conclusions: The application of TST-170 panel based NGS in clinical and laboratory setting is expected to improve diagnostic accuracy and prognostication. Most benefits are expected in IDH-wildtype DG, a group of genetically heterogenous tumors harboring DNA sequence changes, copy number alterations, and fusions in a large number of oncogenes and tumor suppressor genes.

AB - Purpose: The TruSight Tumor 170 (TST-170) panel consists of a DNA workflow for the identification of single-nucleotide variants, small insertions and deletions, and copy number variation, as well as a panel of 55 genes for a RNA workflow for the identification of splice variants and gene fusions. To date, the application of TST-170 in diffuse gliomas (DGs) has not been described. Methods: We analyzed 135 samples of DG, which were diagnosed by WHO criteria based on histological features and conventional molecular tests including immunostaining, 1p/19q FISH, and analysis of MGMT methylation and TERT promoter mutation. Results: A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant. DNA analysis enabled the detection of all mutations identified in these samples by conventional techniques, and the results were highly comparable to the known mutations in each subtype. RNA analysis detected four fusion genes including PTPRZ1–MET, FGFR3–TACC3, FAM131B–BRAF, and RET–CCDC6 and one splicing variant (EGFR vIII mutant). Clustered copy number loss in 1p and 19q loci genes were detected in 1p/19q-codeleted OD. Conclusions: The application of TST-170 panel based NGS in clinical and laboratory setting is expected to improve diagnostic accuracy and prognostication. Most benefits are expected in IDH-wildtype DG, a group of genetically heterogenous tumors harboring DNA sequence changes, copy number alterations, and fusions in a large number of oncogenes and tumor suppressor genes.

UR - http://www.scopus.com/inward/record.url?scp=85060856483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060856483&partnerID=8YFLogxK

U2 - 10.1007/s11060-019-03114-1

DO - 10.1007/s11060-019-03114-1

M3 - Article

C2 - 30710203

AN - SCOPUS:85060856483

VL - 142

SP - 445

EP - 454

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -